All In Biotech

Drug Trial Radar · NCT03406780

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Apr 4, 2018

Primary completion

Mar 10, 2020

Study completion Mar 10, 2020

Sponsor

Lead sponsor
Capricor Inc.Industry
Sponsor type
Industry
First posted
Jan 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.

Conditions

  • Muscular Dystrophies
  • Muscular Dystrophy, Duchenne
  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, X-Linked
  • Genetic Diseases, Inborn

Interventions

  • CAP-1002Biological

    The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Functional Capacity as Assessed by the Mid-level (Elbow) Dimension Score of the Performance of Upper Limb (PUL) Version 1.2 at Month 12Time frame: Baseline, Month 12
  2. Number of Participants Experiencing Acute Respiratory DecompensationTime frame: Baseline through Month 12
  3. Number of Participants With Hypersensitivity ReactionsTime frame: Baseline through Month 12
  4. Number of Participants With All-cause MortalityTime frame: Baseline through Month 12
  5. Number of Participants With Serious Adverse Events (SAEs)Time frame: Baseline through Month 12
  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Investigational Product (IP) or Administration ProcedureTime frame: Baseline through Month 12
  7. Number of Participants With Immune Sensitization SyndromeTime frame: Baseline through Month 12

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital

    Orlando, Florida

  • University of Iowa

    Iowa City, Iowa

  • University of Massachusetts Medical Center

    Worcester, Massachusetts

  • Washington University

    St Louis, Missouri

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • University of Utah

    Salt Lake City, Utah

  • Children's Hospital Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.